Strikingly, high CST1 expression could also predict poor overall survival of breast cancer patients and different subgroups with ER status, PR status, HER-2 status (negative), tumor size, tumor status, lymph node metastasis status (positive), TNM stage (III), or histological stage. This evidence concerns the gene ERBB2 and breast carcinoma.